Final Analysis Of A Phase II Trial Using Sorafenib For Metastatic Castration Resistant Prostate Cancer

OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer (CRPC). Secondary endpoints included pharmacokinetics, toxicity analys...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Aragon-Ching, Jeanny B., Jain, Lokesh, Gulley, James L., Arlen, Philip M., Wright, John J., Steinberg, Seth M., Draper, David, Venitz, Jürgen, Jones, Elizabeth, Chen, Clara C., Figg, William D., Dahut, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2818665/
https://ncbi.nlm.nih.gov/pubmed/19154507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2008.08327.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados